English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Significant advances have been made in the study of neuroprotection and neural regeneration following spinal cord injury (SCI). However, there is wide variability in the animal models used for these studies. Moreover, there is no consensus on which outcome measures are best used to document recovery in animals. On top of these issues, the transfer of research from the laboratory into clinical trials is also hampered by a lack of sensitive outcome measures to document the recovery of function in humans with SCIs. This paper identifies specific issues related to the transfer of research findings from animals into humans. In the laboratory, these issues include the choice of animal model and outcome measures selected; and in humans, the standardization of medical treatment and other therapies, patient selection, and the outcome measures chosen. In the transfer of research from animals into humans, safety and feasibility issues must also be considered.

From the bench to the body: Key issues associated with research aimed at a cure for SCI